プライム・メディスン
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.24 | $1M | -$41M |
| 2026 Q1 | -0.28 | $856,000 | -$43M |
| 2025 Q4 | -0.26 | $838,000 | -$38M |
| 2025 Q3 | -0.32 | $1M | -$35M |
| 2025 Q2 | -0.41 | $1M | -$43M |
| 2025 Q1 | -0.40 | $1M | -$51M |
| 2024 Q4 |
| -0.36 |
| $2M |
| $14M |
| 2024 Q3 | -0.44 | $209,000 | -$27M |